Skip to content

Genomic profiling analysis of clinical sarcomas: a multicenter, non-randomized, open and authentic study

Genomic profiling analysis of clinical sarcomas: a multicenter, non-randomized, open and authentic study

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025163
Enrollment
Unknown
Registered
2019-08-15
Start date
2019-08-12
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma

Interventions

Gold Standard:Pathologic diagnosis
Index test:Genomic&#32
profiling&#32
analysis&#32
by&#32

Sponsors

The First Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Above 1 year old, gender is not limited; 2. Patients have been diagnosed or suspected with osteosarcoma, liposarcoma, chondrosarcoma, fibrosarcoma, Ewing's sarcoma family tumors, synovial sarcoma, leiomyosarcoma, and other sarcomas (malignant peripheral neurilemmoma, alveolar soft tissue sarcoma, rhabdomyosarcoma, hyaline cell sarcoma, ligamentous fibroma, etc.); 3. At least one measurable lesion (RECIST v1.1); 4. The score of functional status was more than or equal to 50%. Karnofsky criterion was used for patients over 16 years old and Lansky criterion was used for patients under 16 years old; 5. Subjects volunteered to participate in the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. CT/MRI Tumors with unclear margins and no measurable lesions; 2. The patients had multiple primary tumors at the same time; 3. Drug abuse; or any medical, psychological or social condition that may affect research, unstable patient compliance, or even endanger patient safety; 4. Participate in another clinical study that has an impact on the results of this study; 5. In a comprehensive assessment, the researchers did not consider it suitable for the patients who participated in this study.

Design outcomes

Primary

MeasureTime frame
The guiding Significance of NGS in Pathological Assisted Diagnosis of Sarcoma in China;The gene profiling of major Sarcoma types in Chinese Population;

Countries

China

Contacts

Public ContactJingnan Shen

The First Affiliated Hospital, Sun Yat-Sen University

shenjn@mail.sysu.edu.cn+86 13609715296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026